Precision medicine has been getting more attention in lung cancer treatment. Here, we report an unusual case of a 71-year-old Chinese male patient with poorly differentiated lung adenocarcinoma with lymph node metastasis. A 5 years' treatment history of this patient is reported. By serial genetic tests of circulating tumor DNA (ctDNA) from peripheral blood and sediment cell genomic DNA (PE-sDNA) from pleural effusion, a novel chronological combination treatment of icotinib, osimertinib, and crizotinib was adopted for the present genetic mutations, including EGFR exon 19 deletion, EGFR p.T790M, and MET amplification.
Keywords: EGFR mutation; MET amplification; ctDNA and PE-sDNA; lung adenocarcinoma; serial genetic monitoring.
Copyright © 2020 Miao, Mu, Liu, Rao, Jin, Wang, Wang, Lu, Gong, Zheng, Zheng, Li, Li, Chen and Shu.